Abstract: The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation.

Abstract: The present invention relates to stabilized gastroretentive tablets comprising pregabalin, one or more swellable polymers, a pH modifier, and other pharmaceutically acceptable excipients. It also relates to processes for the preparation of said stabilized gastroretentive tablets of pregabalin.

Abstract: The present invention relates to a method of imparting crush-resistance to an oral solid dosage form comprising a drug prone to abuse, so as to prevent the unintended and illicit use of the dosage form.

Abstract: The present invention relates to a once daily tablet comprising doxycycline at sub-antibiotic dose and one or more pharmaceutically acceptable excipients, wherein the tablet exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline tablet with or without food. A process of preparing the tablet is also provided.

Abstract: The present invention relates to a method for preparing a stable extended release suspension composition comprising multiple coated cores of an active ingredient by using a suspension base, wherein the suspension base ensures substantially similar in-vitro dissolution release profile of the active ingredient upon storage of the suspension compositions for at least seven days.

Abstract: The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling polymer, wherein the cores are dispersed in a suspension base. It also relates to processes for the preparation of said extended release liquid compositions.

Abstract: The present invention relates to extended release suspension compositions of an active ingredient. Said extended release suspension compositions comprise multiple coated cores of the active ingredient and a suspension base, wherein the suspension base generates a hypertonic condition such that there is no substantial change in the in-vitro dissolution release profile of the extended release suspension compositions upon storage for at least seven days. The invention also relates to processes for the preparation of said extended release suspension compositions.

Abstract: The present invention relates to a gastroretentive tablet comprising pregabalin, at least one swellable polymer, and other pharmaceutically acceptable excipients. It further relates to a process for the preparation of same.

Abstract: The present invention relates to pulsatile-release dosage forms wherein said dosage forms provide pH-independent pulsatile-release of a drug after a predetermined lag time. It also relates to processes for the preparation of said pulsatile-release dosage forms.

Abstract: The present invention relates to a once daily pharmaceutical composition comprising doxycycline and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline pharmaceutical composition with or without food. A process of preparing such pharmaceutical composition is also provided.

Abstract: The present invention relates to a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients. The invention further provides a method of treatment of rosacea by administering such pharmaceutical composition. A process of preparing such pharmaceutical composition is also provided.

Abstract: The present invention relates to a low dose pharmaceutical composition comprising 32 mg or 34 mg doxycycline and one or more pharmaceutically acceptable excipients for the treatment of acne, and processes for its preparation.

Abstract: The present invention relates to timed extended-release pharmaceutical compositions comprising metoprolol and an extended-release polymer. The pharmaceutical compositions of the present invention exhibit an in-vivo lag time of at least 2 hours as and a Tmax of more than 8 hours. Further, said pharmaceutical compositions provide an in-vitro release of metoprolol over a period of at least 20 hours.

Abstract: The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation.

Abstract: The present invention relates to a low dose pharmaceutical composition comprising 24 mg to 36 mg doxycycline and one or more pharmaceutically acceptable excipients for the treatment of acne and/or rosacea, and processes for its preparation.

Abstract: The present invention relates to a pharmaceutical gastro-retentive solid oral dosage form comprising nilotinib as the active ingredient. The invention is further related to methods of preparing said dosage form.

Abstract: The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.

Abstract: The present invention relates to a once daily tablet comprising doxycycline at sub-antibiotic dose and one or more pharmaceutically acceptable excipients, wherein the tablet exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline tablet with or without food. A process of preparing the tablet is also provided.

Abstract: The present invention provides an oral pharmaceutical composition of isotretinoin with a reduced dose. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.

Abstract: The present invention provides an oral pharmaceutical composition of isotretinoin with reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.